| Dr Kelly Daylyn Pizzo, MD | |
|
161 Marginal Way, Portland, ME 04101-2438 | |
| (207) 773-7964 | |
| (207) 773-9073 |
| Full Name | Dr Kelly Daylyn Pizzo |
|---|---|
| Gender | Female |
| Speciality | Gastroenterology |
| Experience | 11 Years |
| Location | 161 Marginal Way, Portland, Maine |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1376986513 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | MD23093 (Maine) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Maine Medical Center | Portland, ME | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mainehealth | 7517860588 | 2067 |
| Portland Gastroenterology Associates Pa | 5193702967 | 21 |
News Archive
"Around 2.1 million Somalis still need food aid and are facing a critical situation despite a fall in the number of people at risk in the last six months, the United Nations said Tuesday," Agence France-Presse reports.
The State Department is attempting to change how it handles mental health services for employees with high-stress jobs, "but there's still a great deal of stigma attached to seeking this kind of help," an internal report says.
ProNAi Therapeutics Inc., a private hematology/oncology company dedicated to developing and commercializing a new class of therapeutics based on its proprietary DNAi platform, today reported that the first patient with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) has enrolled in the "Wolverine" Phase II study and been treated with PNT2258.
A phase III clinical trial of an investigational Alzheimer's disease drug dimebon failed to show encouraging results dooming its future according to its commercial sponsors.
› Verified 6 days ago
| Entity Name | Maine Medical Partners |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598780447 PECOS PAC ID: 9335043967 Enrollment ID: O20040220000847 |
News Archive
"Around 2.1 million Somalis still need food aid and are facing a critical situation despite a fall in the number of people at risk in the last six months, the United Nations said Tuesday," Agence France-Presse reports.
The State Department is attempting to change how it handles mental health services for employees with high-stress jobs, "but there's still a great deal of stigma attached to seeking this kind of help," an internal report says.
ProNAi Therapeutics Inc., a private hematology/oncology company dedicated to developing and commercializing a new class of therapeutics based on its proprietary DNAi platform, today reported that the first patient with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) has enrolled in the "Wolverine" Phase II study and been treated with PNT2258.
A phase III clinical trial of an investigational Alzheimer's disease drug dimebon failed to show encouraging results dooming its future according to its commercial sponsors.
› Verified 6 days ago
| Entity Name | Portland Gastroenterology Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508087289 PECOS PAC ID: 5193702967 Enrollment ID: O20040630000866 |
News Archive
"Around 2.1 million Somalis still need food aid and are facing a critical situation despite a fall in the number of people at risk in the last six months, the United Nations said Tuesday," Agence France-Presse reports.
The State Department is attempting to change how it handles mental health services for employees with high-stress jobs, "but there's still a great deal of stigma attached to seeking this kind of help," an internal report says.
ProNAi Therapeutics Inc., a private hematology/oncology company dedicated to developing and commercializing a new class of therapeutics based on its proprietary DNAi platform, today reported that the first patient with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) has enrolled in the "Wolverine" Phase II study and been treated with PNT2258.
A phase III clinical trial of an investigational Alzheimer's disease drug dimebon failed to show encouraging results dooming its future according to its commercial sponsors.
› Verified 6 days ago
| Entity Name | Mainehealth |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790265502 PECOS PAC ID: 7517860588 Enrollment ID: O20040701000166 |
News Archive
"Around 2.1 million Somalis still need food aid and are facing a critical situation despite a fall in the number of people at risk in the last six months, the United Nations said Tuesday," Agence France-Presse reports.
The State Department is attempting to change how it handles mental health services for employees with high-stress jobs, "but there's still a great deal of stigma attached to seeking this kind of help," an internal report says.
ProNAi Therapeutics Inc., a private hematology/oncology company dedicated to developing and commercializing a new class of therapeutics based on its proprietary DNAi platform, today reported that the first patient with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) has enrolled in the "Wolverine" Phase II study and been treated with PNT2258.
A phase III clinical trial of an investigational Alzheimer's disease drug dimebon failed to show encouraging results dooming its future according to its commercial sponsors.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Kelly Daylyn Pizzo, MD 161 Marginal Way, Portland, ME 04101-2438 Ph: (207) 773-7964 | Dr Kelly Daylyn Pizzo, MD 161 Marginal Way, Portland, ME 04101-2438 Ph: (207) 773-7964 |
News Archive
"Around 2.1 million Somalis still need food aid and are facing a critical situation despite a fall in the number of people at risk in the last six months, the United Nations said Tuesday," Agence France-Presse reports.
The State Department is attempting to change how it handles mental health services for employees with high-stress jobs, "but there's still a great deal of stigma attached to seeking this kind of help," an internal report says.
ProNAi Therapeutics Inc., a private hematology/oncology company dedicated to developing and commercializing a new class of therapeutics based on its proprietary DNAi platform, today reported that the first patient with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) has enrolled in the "Wolverine" Phase II study and been treated with PNT2258.
A phase III clinical trial of an investigational Alzheimer's disease drug dimebon failed to show encouraging results dooming its future according to its commercial sponsors.
› Verified 6 days ago
Andrew J. Hsu, M.D. Gastroenterology Medicare: Medicare Enrolled Practice Location: 155 Fore River Pkwy, Portland, ME 04102 Phone: 207-535-1100 Fax: 207-879-8787 | |
David A Polisner, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 144 State St, Portland, ME 04101 Phone: 207-879-3000 | |
Dr. Elizabeth A Jacobs, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 22 Bramhall St, Portland, ME 04102 Phone: 207-662-0111 | |
Brian D Moore, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 144 State St, Portland, ME 04101 Phone: 207-879-3000 | |
Marc Stuart Hoffman, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 144 State St, Portland, ME 04101 Phone: 207-879-3265 | |
Janet D Mcculley, D.O. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 22 Bramhall St, Portland, ME 04102 Phone: 207-662-4618 | |
Saeeda Fatima, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 22 Bramhall St Rm 2227, Portland, ME 04102 Phone: 207-662-4618 |